AN2 Therapeutics, Inc.
ANTXNasdaqCIK 1880438HealthcareFiscal year ends Dec 31
Reports and events: 68 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-08-1120:04 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-344569 |
| 2026-08-1120:01 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-344549 |
| 2026-06-0922:23 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-262264 |
| 2026-06-0420:15 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-257430 |
| 2026-05-1120:08 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-216755 |
| 2026-05-1120:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-216752 |
| 2026-04-2220:01 ET | DEF 14A | Proxy statementPeriod 2026-04-22 | 0001193125-26-170314 |
| 2026-04-0921:03 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-149822 |
| 2026-03-2020:37 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-117765 |
| 2026-03-1720:03 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-110693 |
| 2026-03-1720:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-110681 |
| 2026-03-1001:43 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-099169 |
| 2026-01-2921:45 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-029540 |
| 2025-11-1221:21 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-277673 |
| 2025-11-1221:19 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-277662 |
| 2025-08-1220:06 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-107301 |
| 2025-08-1220:02 ET | 8-K | 9.01 Financial statements and exhibits | 0000950170-25-107278 |
| 2025-06-2011:00 ET | 8-K | 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-25-143187 |
| 2025-06-1815:08 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001373604-25-000092 |
| 2025-06-1111:30 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-138796 |
| 2025-05-3021:46 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001373604-25-000086 |
| 2025-05-2720:30 ET | 8-K | 5.07 Shareholder vote results | 0001193125-25-127595 |
| 2025-05-1320:12 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-070358 |
| 2025-05-1320:05 ET | 8-K | 9.01 Financial statements and exhibits | 0000950170-25-070305 |
| 2025-05-0714:27 ET | SCHEDULE 13D | Ownership report, active investor | 0001373604-25-000074 |
| 2025-05-0120:27 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-110019 |
| 2025-04-1020:05 ET | DEF 14A | Proxy statementPeriod 2025-04-10 | 0000950170-25-052852 |
| 2025-03-2520:07 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-044366 |
| 2025-03-2520:03 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-044353 |
| 2024-11-1321:04 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-126282 |
| 2024-11-1321:02 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-126276 |
| 2024-11-0521:05 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-24-251240 |
| 2024-08-1910:04 ET | 8-K | 1.01 Entry into a material agreement; 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-24-202430 |
| 2024-08-1320:15 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-096243 |
| 2024-08-1320:06 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-096173 |
| 2024-08-0820:50 ET | 8-K | 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-197047 |
| 2024-06-2420:06 ET | 8-K | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-24-166938 |
| 2024-05-1420:12 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-059556 |
| 2024-05-1420:07 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-059527 |
| 2024-05-1420:01 ET | 10-K/A | Annual report, amendedPeriod 2023-12-31 | 0000950170-24-059488 |
| 2024-04-2620:15 ET | DEF 14A | Proxy statementPeriod 2024-06-19 | 0000950170-24-049148 |
| 2024-03-2920:24 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-038681 |
| 2024-03-2820:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-038055 |
| 2024-02-1212:01 ET | 8-K | 8.01 Other events | 0001193125-24-031008 |
| 2023-11-0921:15 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-062081 |
| 2023-11-0921:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-062046 |
| 2023-09-1312:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-233934 |
| 2023-09-0821:37 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-23-230786 |
| 2023-08-1620:47 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-23-214362 |
| 2023-08-1020:25 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0000950170-23-041378 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:06 ET. Listed shows no prices and gives no investment advice.